Lobular Breast Cancer: Moon Shot Project

Scott Arthur Excerpts

Thursday 9th July 2026 Westminster Hall

[Dr Scott Arthur (Edinburgh South West) (Lab)]

It is a pleasure to serve under you in the Chair, Mrs Hobhouse. Like others, I thank the hon. Member for Horsham (John Milne) for introducing the debate and for how he did it.

I want to make a prediction. I think the remaining speakers are going to say that they support this campaign and that they want to see a difference, and they will acknowledge the gap that needs to be filled. Our challenge is making that pledge and those words real. I have been in debates like this before—we all agree that something has to be done, yet we come back and speak about it again and again. Perhaps, if we all carry this campaign forward, this is the time to actually make it happen.

[Sam Rushworth]

My hon. Friend just made an excellent point. We know the research questions that need to be answered. Does he agree that it should not be beyond UKRI to put out a specific call asking people, through a competitive peer review process, to answer those questions?

[Dr Arthur]

Exactly. In a former life, I was an academic. UKRI does at times engage with academics to fine-tune such questions. UKRI provides funding to universities, if needed, to bring the very best people to the UK either temporarily or on longer-term contracts to help to make a difference in the UK. Those things are perhaps all part of the solution. My hon. Friend is absolutely right.

I am grateful for the opportunity to support this vital debate. It shines much-needed light on a disease that is still under-resourced, as has been said, and it honours the legacy of a woman who dedicated her final years to fighting it: the late Susan Michaelis. I was not fortunate enough to meet her but, as a result of the excellent introduction of the hon. Member for Horsham, I feel I know a little bit about her and her character. I am grateful for that introduction.

Lobular breast cancer, despite being the second most common form of breast cancer, has historically received a mere 1% of breast cancer research funding. Susan refused to accept that disparity and the Lobular Moon Shot Project is her legacy—but it has to be more than a project. Hopefully, progress will be her real legacy. The project demands better treatment for every woman who receives a lobular breast cancer diagnosis. That is why all of us are in the Chamber for this debate.

I recently received an incredibly powerful letter from a leading oncologist, Dr Michie. She is based in Edinburgh, treats patients in Scotland and works closely with the community of those with lobular breast cancer. She expressed deep professional frustration on behalf of her patients, explicitly stating that lobular breast cancer has been neglected for too long. People who meet patients day in, day out and week in, week out still have a real frustration about the lack of progress. Dr Michie’s letter also highlighted the fact that lobular breast cancer is different from the more common ductal types of breast cancer, with an entirely unique tumour biology, different responses to drug treatments, and distinct and highly challenging patterns of spread.

The different response to drug treatments is really important because, in the absence of proper treatments, women are often faced with a drug that was not actually designed for the condition that they have. Yet clinical trials rarely even present separate response data for lobular cases: today a grand total of zero lobular-specific clinical trials are actively recruiting patients in the UK. That should shame us, based on what we have discussed already in this debate, and on the scale and breadth of the campaign that has been run.

Additionally, the incidence of lobular breast cancer is rising rapidly, climbing by nearly 3% annually. Because it does not form the typical lump, it is notoriously difficult to detect using classical imaging. That is 3% annual growth in diagnoses of this condition—I know that, as a Government, we are really keen on growth but not that kind. To fix it, we need to improve our pre-clinical understanding of how and why the disease spreads. I believe that the work package plan of the Lobular Moon Shot Project is precisely the kind of ambitious and collaborative plan that can help us to improve patient outcomes across the board. If people do not believe that, let us have a conversation about how it can be improved.

[Seamus Logan (Aberdeenshire North and Moray East) (SNP)]

The hon. Member speaks about the value of research. Some 50 years ago this year, my cousin was diagnosed with breast cancer. She had three years. She left five children under the age of 10. Yesterday I met Lesley, who was diagnosed 20 years ago. Lesley is well. She is still receiving treatment, but that demonstrates the value of the advances that research can make. Does the hon. Member agree that it is absolutely vital that we invest in this area?

[Dr Arthur]

Absolutely. Yesterday I met with activists from Cancer Research UK just outside Parliament, before they came in. Cancer Research UK had around 100 activists there who had been touched by cancer, in all its shapes and forms, and although that big room was full of people who were full of energy, they were just a tiny part of the footprint of cancer and its impacts across the UK—absolutely tip-of-the-iceberg stuff.

We have to acknowledge the emotional impact on individuals and families, but also the economic impact. We should never be ashamed of talking about that. There is also the economic impact of bringing the best research to the UK so that our laboratories, universities and hospitals can work on this issues. All that is a push in the right direction.

The Government and the bio-sciences sector are notoriously slow-moving. We need to expedite work in this area; a dedicated funding commitment from the Government to launch the Moon Shot Project would help do that. When we talk about housing, we talk about being builders not blockers. Maybe we should use the same narrative and energy for this matter.

On a related note, while the fight for a new funding model is critical, we cannot afford to overlook the importance of immediate and compassionate support for people who have the condition. In my constituency we are incredibly fortunate to have the House of Hope, a wonderful charity that provides a safe space for women navigating a breast cancer diagnosis and for their families, including their husbands and children. As I understand it, they plan to start a support group to focus specifically on lobular breast cancer, which will meet for the first time on 11 August. I wish them well in that endeavour and I am wearing my House of Hope badge today. They actually gave me three badges with different designs, but I went for the glittery one because we all need a bit of glitter in our lives sometimes.

I have always found the House of Hope to be an incredibly inspiring and hospitable place. I encourage any woman with a diagnosis in Edinburgh and the Lothians or further afield to check out the services it provides. I am sure the Minister would be welcome to visit any time and I can guarantee him it will be cooler in Edinburgh than it is in London right now.

I return to Susan and her project. A clear and fundamental shift is needed in how we fund and prioritise research into this condition. I strongly encourage the Minister to actively engage with the project’s demands, meet with the campaign and agree a plan going forward for how we can address their concerns. As has been said already, 22 women will be diagnosed with this condition today and we need to give them and their families hope.

I checked Hansard this morning: in the 2019 to 2024 Parliament, lobular breast cancer was mentioned 10 times. Just two years into the current Parliament, we have mentioned it 56 times. We need to stop talking about it in this place and actually start getting stuff done.

--- Later in debate ---

[Stephen Kinnock]

Okay. I thank the hon. Lady. That is what we will do.

[Dr Arthur]

I appreciate that the Minister is substituting for another excellent Minister, my hon. Friend the Member for Washington and Gateshead South (Mrs Hodgson); I am sad that she is not here, because she is fantastic. We ringfence money for brain tumour research—I know that that community wants more money, so I am not saying it is the gold standard, but we have made that choice, because we recognised the public concern about brain tumours. There is also public concern about lobular breast cancer and the feeling that people who have it are being left behind. It is fantastic that we have better screening coming on board, but ultimately people need treatment if they are diagnosed during the screening process.

The Minister highlighted the fact that there is a competitive bidding process. Is it the case that the bids are not good enough? If that is the case, can we invest money to improve the quality of those bids? As I said earlier, we could bring in better staff, perhaps from overseas, or invest in PhD students to work in this area.

[Stephen Kinnock]

My understanding is that there are bids that are good enough and they are the ones that have attracted funding for research into lobular breast cancer. What I do not know at this moment is precisely where the live bids are and whether they are making the cut in terms of the quality that we are looking for. I will absolutely follow up with my ministerial colleague, and I will write to my hon. Friend on that point.